Strategic Assets

Strategic Assets

Royalty Assets

 

Innoviva’s royalty portfolio is partnered with GlaxoSmithKline and addresses a $20+ billion global respiratory treatments market. Our diversified, durable product portfolio includes innovative asthma and chronic obstructive pulmonary disease (COPD) medicines with compelling, differentiated therapeutic profiles; portfolio management is a key value driver.

Relvar Breo Ellipta

RELVAR®/BREO® is a once-a-day combination inhaled respiratory medicine consisting of vilanterol (VI), a long-acting beta2-agonist (LABA), and fluticasone furoate (FF), an inhaled corticosteroid (FF/VI), delivered via the ELLIPTA® dry powder inhaler.

Approved for COPD/Asthma and marketed globally.

MyBreo

Anoro Ellipta

ANORO® ELLIPTA® is a dual bronchodilator consisting of umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA), and vilanterol (VI), a long-acting beta2-agonist (LABA) for the treatment of chronic obstructive pulmonary diseases (COPD). This once-a-day combination inhaled respiratory medicine is delivered via the ELLIPTA® dry powder inhaler.

Approved for COPD and marketed globally.

Anoro

Trelegy Ellipta

TRELEGY® ELLIPTA® is a combination of fluticasone furoate (FF), an inhaled corticosteroid (ICS); umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA); and vilanterol (VI), a long-acting beta2-adrenergic agonist (LABA). TRELEGY® ELLIPTA® is indicated for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) and to reduce exacerbations of COPD in patients with a history of exacerbation. TRELEGY® ELLIPTA® is also indicated for the maintenance treatment of asthma in patients aged 18 years and older. This three-way combination inhaled respiratory medicine is self-administered by patients through the ELLIPTA® dry powder inhaler.

Trelegy

Bar Chart of annual royalties

Other Selected Strategic Assets

 

Innoviva seeks to diversify its primary royalty management business through actively pursuing opportunistic acquisitions of promising companies and assets in the healthcare industry. We prioritize highly innovative companies addressing areas of significant unmet medical need in order to create both societal and financial value.  We are very selective and thoughtful in our approach, taking a targeted view with concentrated, long-term positions and focusing on large-stake investments.  Once committed, we seek to form strategic partnerships with companies of interest, supporting their development into best-in-class businesses.  We believe that, aside from significant financial resources, we also bring to the table superb operating capabilities that can meaningfully accelerate value creation.  In the recent past, we have built a presence in infectious diseases but remain open to other therapeutic areas. 

Collaborative, thoughtful approach to everything we do

Long-term strategic partner with commitment spanning years

Interest in and differentiated ability to help companies succeed

Armata Pharma

Armata Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology.

Armata’s lead candidate, AP-PA02, is a therapeutic phage cocktail that targets the pathogen aeruginosa, to treat serious respiratory infections, with an initial emphasis on cystic fibrosis (CF) patients. It is currently in mid-stage clinical development.

Location: Marina del Rey, CA
Founded: 2019

Armata

Entasis Therapeutics

Entasis Therapeutics Holding Inc. is an advanced, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted antibacterial products that address high unmet medical needs to treat serious infections caused by multidrug-resistant pathogens. It was spun out from AstraZeneca, retaining rights to the company’s industry-leading discovery and early development small-molecule anti-infectives portfolio.

Entasis’ lead candidate, sulbactam-durlobactam, is a combination of β-lactam antibiotic and a β-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter, including multidrug-resistant (MDR) strains. It is currently in late-stage clinical development.

Location: Waltham, MA
Founded: 2015

Entasis